hyperkalaemia

This page shows the latest hyperkalaemia news and features for those working in and with pharma, biotech and healthcare.

NICE says no to AZ and Vifor’s rival hyperkalaemia drugs

Between 1% and 10% of hospital inpatients have hyperkalaemia. Many patients won’t display any symptoms, but some severe cases can lead to cardiac arrest. ... Hyperkalaemia is also seen in patients taking common medications for heart failure, such as

Latest news

AZ gets US approval for Veltassa rival Lokelma

AZ gets US approval for Veltassa rival Lokelma. But GlobalData predicts Veltassa has the edge due to positive data in chronic hyperkalaemia. ... AstraZeneca has picked up FDA approval for its hyperkalaemia treatment Lokelma, allowing it to compete head-to
Daily Brief: AI to boost early NHS cancer diagnosis, AZ shareholder revolt, Juluca approval

The company has a number of promising new cancer treatments, and has just received FDA approval for the delayed hyperkalaemia drug Lokelma.
AZ finally gets EU nod for Veltassa rival Lokelma

AZ finally gets EU nod for Veltassa rival Lokelma. And expects a US FDA verdict for the hyperkalaemia treatment later this year. ... The approval of Lokelma “addresses a significant unmet need by bringing a rapid and sustained therapeutic option for
Vifor wins European approval for Veltassa

Vifor wins European approval for Veltassa. European Commission approves the drug to treat hyperkalaemia. ... The European Commission (EC) has approved Vifor’s Veltassa (patiromer) to treat adults with hyperkalaemia, a potentially life threatening
FDA turns down AZ's ZS-9 once again on manufacturing issues

The US regulator issued a Complete Response Letter to ZS Pharma regarding its application for ZS-9 (sodium zirconium cyclosilicate) as a treatment for the condition - known as hyperkalaemia - after an ... Veltassa was launched in early 2016 - becoming

More from news
Approximately 5 fully matching, plus 8 partially matching documents found.

Latest Intelligence

Deal Watch July 2016

for the treatment of hyperkalaemia.
Deal Watch November 2015

Paying $90 per share (headline value $2.7bn) in acquiring ZS Pharma, AstraZeneca gains access to ZS-9, a possible best in class product for hyperkalaemia which is under FDA review. ... ZS Pharma. AstraZeneca. Acquisition - company. Lead product ZS-9,
Pharma deals during October 2013

Examples of recent IPOS. Company. Product/technology. Target ($m). Relypsa. Patiromer for hyperkalaemia in chronic kidney disease (phase III).

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Senior Account Director development role to Business Director, H...: Excellent package

Medical Writer – Health Behaviour/ Patient Adherence Agency: Salary TBC

Account Manager, Healthcare Public Affairs: £32, 000 – £40, 000 benefits

Programme Director, Healthcare PR, Highly competitive package: Highly Competitive package

Medical Writers: Competitive Salary and Benefits

Associate Editorial Director – Med Comms – London: Salary TBC

Account Manager – Creative Healthcare Advertising – Central Lond...: Salary TBC

Senior Medical Writer (Remote Working): Competitive Salary Offered

Account Manager / Account Director: Competative

Freelance Account Manager / Senior Account Manager - Medical Edu...: £300 per day

Senior Account Executive, London, Medical Communications: Excellent package

Consultant Health Economics - London / Oxford: Negotiable

Leadership opportunity, Pricing & Market Access, UK, Substan...: Substantial six figure package

Client Services Director – Medical Education Agency – North West...: Salary TBC

Senior Account Manager > Account Director - London - Medical ...: Salary TBC

Events Manager – Med Comms – Surrey: Salary TBC

Senior Account Manager- Central Oxford and Abingdon: Negotiable

Account Director: £48, 000 - £60, 000

Scientific Director – Medical Communications - New York or Remot...: $100000 - $150000

Senior Medical Writer: Great salary and benefits

Director, Market Access / HEOR - North-West: Negotiable

Production Manager – Healthcare Communications: DOE

Senior Systematic Review Analyst - Oxford: Negotiable

New Business Director - PR: Competitive Salary and benefits

Associate Medical Director: Highly Competitive

Subscribe to our email news alerts

PMHub

Add my company

HAVAS LYNX

Welcome to HAVAS LYNX, a leading global healthcare communications group....

Latest intelligence

OUTiCO win Best in UK Pharmaceutical Outsourcing award: The Corporate LiveWire Healthcare and Life Sciences Awards celebrate global companies and individuals who have excelled over the past 12 months....
Artificial Intelligence in Healthcare: Artificial intelligence is already out-diagnosing experts, but would you put a computer in charge of your healthcare? The good, the bad; we take a look....
World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer: Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...